Clare Loudon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clare Loudon has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer M. S. Koh
The University of Sydney 1 ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health Westmead, Australia
7 shared publications - Peter G. Hains
ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia
7 shared publications - Phillip J. Robinson
Children’s Medical research Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
7 shared publications - Roger R. Reddel
ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
7 shared publications - Adel T. Aref
ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia
6 shared publications - Adnan Nagrial
The University of Sydney, Sydney, Australia
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
List of the differentially abundant proteins across the High-risk vs Low-risk proteomic groups based on the “limma” analysis.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
List of the differentially abundant proteins across the High-risk vs Low-risk proteomic groups based on the “limma” analysis.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Number of mass spectrometry runs for each cohort and the number of identified peptides and proteins.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Number of mass spectrometry runs for each cohort and the number of identified peptides and proteins.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S22 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Supplementary Figure 1: CONSORT diagram. Supplementary Figure 2: Summary of the workflow to develop the proteomic-based risk score. Supplementary Figure 3: Evaluation of different cut-off points for the risk score in the training cohort. Supplementary Figure 4: The intensities of the six proteins included in the risk score among the normal (n = 67) and tumor (n = 175) tissue samples in the Training cohort. Supplementary Figure 5: The intensities of the six proteins included in the risk score among the relapse and non-relapse groups in the A) Training cohort (Cohort 1), B) The first validation cohort (Cohort 2), and C) The second validation cohort (Cohort 3). Supplementary Figure 6: The intensities of the six proteins included in the risk score in the three cohorts among (A-C) Tumor (T)-stage; (D-F) Nodal (N)-stage; (G-I) Tumor side and (J-L) Tumor grade. Supplementary Figure 7: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 1. Supplementary Figure 8: A receiver operating characteristic curve (ROC) showing the Area Under the Curve (AUC) of different models including clinical variables with and without the risk score in the training cohort (Cohort 1). Supplementary Figure 9: Kaplan-Meier analyses showing the association of proteomic risk score in Cohort 1 with the risk of recurrence among subgroup of patients with A) MSI High, B) MSI Stable, C) Left-sided tumor, D) Right-sided tumor, E) Adjuvant Chemotherapy, F) No Adjuvant Chemotherapy, G) Mucinous subtype, H) Non-mucinous subtype. MSI: Microsatellite Instability. Supplementary Figure 10: Kaplan-Meier analyses showing the association of adjuvant chemotherapy with risk of recurrence in A) Whole training cohort (Cohort 1), B) Among patients in the high proteomic risk group and C) Among patients in the low proteomic risk group. D) A nomogram including the proteomic risk score and clinical variables. Supplementary Figure 11: Pathway enrichment analysis related to the proteins differentially abundant in high- vs low-risk proteomic group. Supplementary Figure 12: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 2. Supplementary Figure 13: A receiver operating characteristic curve (ROC) showing the area under the curve (AUC) of different models including clinical variables with and without the risk score in the first validation cohort (Cohort 2). Supplementary Figure 14: Kaplan-Meier analyses showing the association of the proteomic risk score with risk of recurrence within subgroups of patients with A) High clinical risk (T4 and/or N2) or B) Low clinical risk (T1-3/N0-1) in Cohort. 2 Supplementary Figure 15: Risk of recurrence within Cohort 2 including the subgroups. Supplementary Figure 16: Risk of recurrence in Cohort 2 by adjuvant treatment regimen and duration. Supplementary Figure 17: Kaplan-Meier analyses showing the association of adjuvant chemotherapy regimens in Cohort 2 with risk of recurrence among the different subgroups of patients . Supplementary Figure 18: Prognostic value of the proteomic risk score in Cohort 3. Supplementary Figure 19: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 3. Supplementary Figure 20: A receiver operating characteristic curve (ROC) showing the Area under the curve (AUC) of different models, including clinical variables with and without the risk score in the second validation cohort (Cohort 3). Supplementary Figure 21: Risk of recurrence among different subgroups within Cohort 3. Supplementary Figure 22: Kaplan-Meier analyses of Cohort 3 showing the association of adjuvant chemotherapy with risk of recurrence.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S22 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Supplementary Figure 1: CONSORT diagram. Supplementary Figure 2: Summary of the workflow to develop the proteomic-based risk score. Supplementary Figure 3: Evaluation of different cut-off points for the risk score in the training cohort. Supplementary Figure 4: The intensities of the six proteins included in the risk score among the normal (n = 67) and tumor (n = 175) tissue samples in the Training cohort. Supplementary Figure 5: The intensities of the six proteins included in the risk score among the relapse and non-relapse groups in the A) Training cohort (Cohort 1), B) The first validation cohort (Cohort 2), and C) The second validation cohort (Cohort 3). Supplementary Figure 6: The intensities of the six proteins included in the risk score in the three cohorts among (A-C) Tumor (T)-stage; (D-F) Nodal (N)-stage; (G-I) Tumor side and (J-L) Tumor grade. Supplementary Figure 7: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 1. Supplementary Figure 8: A receiver operating characteristic curve (ROC) showing the Area Under the Curve (AUC) of different models including clinical variables with and without the risk score in the training cohort (Cohort 1). Supplementary Figure 9: Kaplan-Meier analyses showing the association of proteomic risk score in Cohort 1 with the risk of recurrence among subgroup of patients with A) MSI High, B) MSI Stable, C) Left-sided tumor, D) Right-sided tumor, E) Adjuvant Chemotherapy, F) No Adjuvant Chemotherapy, G) Mucinous subtype, H) Non-mucinous subtype. MSI: Microsatellite Instability. Supplementary Figure 10: Kaplan-Meier analyses showing the association of adjuvant chemotherapy with risk of recurrence in A) Whole training cohort (Cohort 1), B) Among patients in the high proteomic risk group and C) Among patients in the low proteomic risk group. D) A nomogram including the proteomic risk score and clinical variables. Supplementary Figure 11: Pathway enrichment analysis related to the proteins differentially abundant in high- vs low-risk proteomic group. Supplementary Figure 12: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 2. Supplementary Figure 13: A receiver operating characteristic curve (ROC) showing the area under the curve (AUC) of different models including clinical variables with and without the risk score in the first validation cohort (Cohort 2). Supplementary Figure 14: Kaplan-Meier analyses showing the association of the proteomic risk score with risk of recurrence within subgroups of patients with A) High clinical risk (T4 and/or N2) or B) Low clinical risk (T1-3/N0-1) in Cohort. 2 Supplementary Figure 15: Risk of recurrence within Cohort 2 including the subgroups. Supplementary Figure 16: Risk of recurrence in Cohort 2 by adjuvant treatment regimen and duration. Supplementary Figure 17: Kaplan-Meier analyses showing the association of adjuvant chemotherapy regimens in Cohort 2 with risk of recurrence among the different subgroups of patients . Supplementary Figure 18: Prognostic value of the proteomic risk score in Cohort 3. Supplementary Figure 19: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 3. Supplementary Figure 20: A receiver operating characteristic curve (ROC) showing the Area under the curve (AUC) of different models, including clinical variables with and without the risk score in the second validation cohort (Cohort 3). Supplementary Figure 21: Risk of recurrence among different subgroups within Cohort 3. Supplementary Figure 22: Kaplan-Meier analyses of Cohort 3 showing the association of adjuvant chemotherapy with risk of recurrence.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Purpose:Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification.Experimental Design:We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence.Results:The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts.Conclusions:The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Purpose:Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification.Experimental Design:We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence.Results:The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts.Conclusions:The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Missingness rate of the six proteins included in the risk score across the three cohorts.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Missingness rate of the six proteins included in the risk score across the three cohorts.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Purpose: Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification. Experimental Design: We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence. Results: The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts. Conclusions: The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Purpose: Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification. Experimental Design: We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence. Results: The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts. Conclusions: The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.
- Open Access
Heat ‘n Beat: A universal high-throughput end-to-end proteomics sample processing platform in under an hour
Proteomic analysis by mass spectrometry (MS) of small (≤2 mg) solid tissue samples from diverse formats requires high throughput and comprehensive proteome coverage. We developed a near universal, rapid and robust protocol for sample preparation, suitable for high-throughput projects that encompass most cell or tissue types. This end-to-end workflow extends from original sample to loading the mass spectrometer and is centred on a one tube homogenisation and digestion method called Heat ‘n Beat (HnB). It is applicable to most tissues, regardless of how they were fixed or embedded. Sample preparation was divided to separate challenges. The initial sample washing, and final peptide clean-up steps were adapted to three tissue sources: fresh frozen (FF), optimal cutting temperature (OCT) compound embedded (FF-OCT), and formalin-fixed paraffin-embedded (FFPE). Thirdly, for core processing, tissue disruption and lysis were decreased to a 7 min heat and homogenisation treatment, and reduction, alkylation and proteolysis were optimised into a single step. The refinements produced near doubled peptide yield, delivered consistently high digestion efficiency of 85-90%, and required only 38 minutes for core processing in a single tube, with total processing time being 53-63 minutes. The robustness of HnB was demonstrated on six organ types, a cell line and a cancer biopsy. Its suitability for high throughput applications was demonstrated on a set of 1,171 FF-OCT human cancer biopsies, which were processed for end-to-end completion in 92 hours, producing highly consistent peptide yield and quality for over 3,513 MS runs. Graphical
Open AccessHeat ‘n Beat: A universal high-throughput end-to-end proteomics sample processing platform in under an hour
Proteomic analysis by mass spectrometry (MS) of small (≤2 mg) solid tissue samples from diverse formats requires high throughput and comprehensive proteome coverage. We developed a near universal, rapid and robust protocol for sample preparation, suitable for high-throughput projects that encompass most cell or tissue types. This end-to-end workflow extends from original sample to loading the mass spectrometer and is centred on a one tube homogenisation and digestion method called Heat ‘n Beat (HnB). It is applicable to most tissues, regardless of how they were fixed or embedded. Sample preparation was divided to separate challenges. The initial sample washing, and final peptide clean-up steps were adapted to three tissue sources: fresh frozen (FF), optimal cutting temperature (OCT) compound embedded (FF-OCT), and formalin-fixed paraffin-embedded (FFPE). Thirdly, for core processing, tissue disruption and lysis were decreased to a 7 min heat and homogenisation treatment, and reduction, alkylation and proteolysis were optimised into a single step. The refinements produced near doubled peptide yield, delivered consistently high digestion efficiency of 85-90%, and required only 38 minutes for core processing in a single tube, with total processing time being 53-63 minutes. The robustness of HnB was demonstrated on six organ types, a cell line and a cancer biopsy. Its suitability for high throughput applications was demonstrated on a set of 1,171 FF-OCT human cancer biopsies, which were processed for end-to-end completion in 92 hours, producing highly consistent peptide yield and quality for over 3,513 MS runs. Graphical